All projects
Medtech
NEUROTYPE
Non-invasive neural decoding that restores fine motor intent after stroke.
CHUV / EPFL Neuro-X joint spinout · Lausanne
AskCHF 4.5M
RoundSeries A
ReadinessA
Founded2023
Team18 people
Raised to dateCHF 2.6M (seed)
Why it is on the platform
Implantable decoding works but is confined to a small patient population. NEUROTYPE's claim is that the same fidelity is reachable non-invasively, which changes the addressable population by an order of magnitude.
Traction
- Two completed clinical feasibility studies at CHUV (n=34).
- Median 41% improvement in Fugl-Meyer score against standard therapy.
- MDR Class IIa submission prepared; notified body engaged.
- Reimbursement dialogue opened with two Swiss insurers.
Use of funds
- Pivotal multi-centre trial across three European hospitals.
- MDR certification through to CE mark.
- Manufacturing transfer to a Swiss contract manufacturer.
Deck highlights
Stage of proofValidated
IP positionFiled / granted
RevenuePre-revenue
Data roomComplete
Team
Prof. Camille Roux
CEO — 14 years in neurorehabilitation
Dr. Tomas Halvorsen
CSO — decoding algorithms, ex-Neuro-X
Sophie Aebi
COO — medical device regulatory, ex-large-cap medtech